Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer

Shanshan Zhao, Milan S. Geybels, Amy Leonardson, Rohina Rubicz, Suzanne Kolb, Qingxiang Yan, Brandy Klotzle, Marina Bibikova, Antonio Hurtado-Coll, Dean Troyer, Raymond Lance, Daniel W. Lin, Jonathan L. Wright, Elaine A. Ostrander, Jian-Bing Fan, Ziding Feng, Janet L. Stanford*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)311-319
Number of pages9
JournalClinical Cancer Research
Volume23
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • BIOCHEMICAL RECURRENCE
  • RADICAL PROSTATECTOMY
  • PROMOTER HYPERMETHYLATION
  • GLEASON SCORE
  • RISK
  • GENE
  • MORTALITY
  • BIOPSY
  • ASSOCIATION
  • SURVIVAL

Cite this

Zhao, S., Geybels, M. S., Leonardson, A., Rubicz, R., Kolb, S., Yan, Q., Klotzle, B., Bibikova, M., Hurtado-Coll, A., Troyer, D., Lance, R., Lin, D. W., Wright, J. L., Ostrander, E. A., Fan, J-B., Feng, Z., & Stanford, J. L. (2017). Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. Clinical Cancer Research, 23(1), 311-319. https://doi.org/10.1158/1078-0432.CCR-16-0549